The Lung
Cancer Clinical Masterclass Series

The essential on-demand “boxset” for Clinicians

Welcome to The Lung Cancer Clinical Masterclass Series which is co-chaired by Raffaele Califano and Samreen Ahmed. This virtual initiative boasts a faculty of 24 guest speakers who are leading clinicians within the lung cancer space.

The Lung Cancer
Clinical Masterclass
Series is proudly
co-chaired by:

Raffaele Califano

The Christie,
Manchester

Biography

Samreen Ahmed

University Hospitals
Leicester

Biography

Available episodes

Episode 1 – May 2023

Screening and Diagnosis of Early Stage Lung Cancer

Available - Click here to view

Haval Balata

Wythenshawe Hospital, Manchester

Topic: Role of Screening for Lung Cancer

Biography

Phil Crosbie

University of Manchester, Manchester

Topic: Challenges to Implementing Biomarker- Based Screening and MRD Detection

Biography

Episode 2 – June 2023

Histological Diagnosis and Genomic Subtyping for Lung Cancer

Available - Click here to view

Keith Kerr

Aberdeen University, Aberdeen

Topic: Role of the Pathologist for the Diagnosis and the Molecular Subtyping of Lung Cancer

Biography

Helene Schlecht

Manchester Centre for Genomic Medicine

Topic: Genomic Screening for Lung Cancer: The Role of Next Generation Sequencing

Biography

Episode 3 – July 2023

Radical Treatment for Non-Small Cell Lung Cancer (NSCLC)

Available - Click here to view

Felice Granato

Wythenshawe Hospital, Manchester

Topic: Role of Surgery for Early-Stage NSCLC

Biography

John Conibear

Barts Cancer Centre, London

Topic: Role of Radical Radiotherapy (Standard or SABR) for NSCLC

Biography

Episode 4 – August 2023

Adjuvant Therapies for Completely Resected Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Available - Click here to view

Tom Newsom-Davis

Chelsea and Westminster Hospital, London

Topic: Role of Adjuvant Targeted Therapies and Immunotherapy for Completely Resected Early-Stage NSCLC

Biography

Episode 5 – September 2023

Radical Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Available - Click here to view

Fiona McDonald

The Royal Marsden Hospital, London

Topic: The Role of Concurrent Chemotherapy Followed by Durvalumab

Biography

Shobhit Baijal

The University Hospital Birmingham, Birmingham

Topic: The Role of Perioperative Immunotherapy for Early-Stage/Locally Advanced NSCLC

Biography

Episode 6 – October 2023

Management of Small Cell Lung Cancer

Available - Click here to view

Corinne Faivre-Finn

The Christie, Manchester

Topic: Management of Limited-Stage Small Cell Lung Cancer

Biography

Raffaele Califano

The Christie, Manchester

Topic: Management of Extensive-Stage Small Cell Lung Cancer (Chemo- Immunotherapy and Beyond)

Biography

Episode 7 – November 2023

Management of Stage IV Non-Small Cell Lung Cancer (NSCLC)

Available - Click here to view

Dionysis Papadatos-Pastos

University College London Hospitals

Topic: The Role of First-Line Immunotherapy or Chemoimmunotherapy for Advanced NSCLC

Biography

Tim Benepal

St Georges University Hospitals, NHS FT

Topic: Second-Line Therapies for Advanced NSCLC

Biography

Episode 8 – December 2023

Management of EGFR-Mutant Stage IV Non-Small Cell Lung Cancer (NSCLC)

Available - Click here to view

Samreen Ahmed

University Hospitals Leicester

Topic: Standard Stratergies for Advanced EGFR-Mutant Stage IV NSCLC

Biography

Carles Escriu

The Clatterbridge Cancer Centre, Liverpool

Topic: What’s New in the Field of EGFR-Mutant Stage IV NSCLC

Biography

Episode 9 – January 2024

Management of ALK and ROS1 Gene Rearranged Non-Small Cell Lung Cancer (NSCLC)

Available - Click here to view

Yvonne Summers

The Christie, Manchester

Topic: Standard Stratergies for Advanced ALK and ROS1-Mutant NSCLC

Biography

Samreen Ahmed

University Hospitals Leicester

Topic: What’s New in the Field of ALK and ROS1-Mutant NSCLC?

Biography

Episode 10 – February 2024

Management of BRAF and KRAS-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Available - Click here to view

Tanya Ahmad

University College London Hospitals

Topic: Treatment of BRAF-Mutant NSCLC

Biography

Helen Adderley

The Christie, Manchester

Topic: Treatment of KRAS-Mutant NSCLC

Biography

Episode 11 – March 2024

Novel Molecularly Driven Targeted Therapies for Non-Small Cell Lung Cancer (NSCLC)

Available - Click here to view

Anna Minchom

Institute of Cancer Research and the Royal Marsden Hospital, London

Topic: Targeting RET and MET Positive Advanced NSCLC

Biography

Alastair Greystoke

Newcastle University, Newcastle

Topic: Targeting EGFR exon-20, NTRK and HER2 Positive Advanced NSCLC

Biography

Episode 12 – April 2024

Management of Mesothelioma

Available - Click here to view

Nadza Tokaca

The Royal Marsden Hospital, London

Topic: First-Line Strategies for Pleural and Peritoneal Mesothelioma

Biography

Dean Fennell

The University of Leicester, Leicestershire

Topic: Strategies for Pre-Treated Mesothelioma: Current Standards and Future Directions

Biography

The essential on-demand “boxset” for Clinicians

Free registration for clinicians

Clinicians

Free access for clinicians to watch all
12 masterclass episodes.

£0

Industry

Paid access for industry individuals to
watch all 12 masterclass episodes.

£499

Biography

Bio Coming soon

Raffaele Califano

The Christie, Manchester

Topic: Management of Extensive-Stage Small Cell Lung Cancer (Chemo- Immunotherapy and Beyond)

Biography

Professor Ahmed has been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine London. She has a research degree (MD) through Nottingham University and received an Honorary Chair in 2016 from the University of Leicester.

Professor Ahmed is the Training Programme Director for Medical Oncology in the East Midlands and Honorary secretary for the Association of cancer Physicians. She is a member of the BTOG Steering Committee and NCRI Lung Cancer Clinical Studies Group. NIHR award winner for clinical trials in 2015.

Samreen Ahmed

University Hospitals Leicester

Topic: Standard Stratergies for Advanced EGFR-Mutant Stage IV NSCLC

Biography

Dr Haval Balata is a Consultant Respiratory Physician based at Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK. He is also an Honorary Senior Lecturer at the School of Biological Sciences, University of Manchester, Manchester, UK.

Specialising in respiratory medicine and thoracic oncology, Dr Balata’s clinical and research interests include the risk reduction, screening and early detection of lung cancer and interventional bronchoscopy. He has published on topics encompassing screening and early detection of lung cancer, diagnostic and treatment pathways as well as post-treatment risk-stratification and surveillance.

Dr Balata enjoys extensive involvement in the pioneering ‘Manchester Lung Health Check’ service for targeted lung cancer screening, having overseen the initial pilot study as part of his PhD thesis in 2016. He is now the active Responsible Clinician for two of the UK’s largest ‘Targeted Lung Health Check’ programmes. His other roles include being the clinical lead for the Interventional Bronchoscopy Unit at Wythenshawe Hospital and clinical lead for the regional Navigation Bronchoscopy service.

Haval Balata

Wythenshawe Hospital, Manchester

Topic: Role of Screening for Lung Cancer

Biography

Professor Crosbie is a Professor of Respiratory Medicine at the University of Manchester. His main clinical and research interest is lung cancer with a specific focus on early detection and screening. He is a member of the national Targeted Lung Health Checks Expert Advisory Group. He is also Early Detection lead for Cancer Research UK’s Lung Cancer Centre of Excellence, co-chief investigator of the Yorkshire Lung Screening Trial and research lead for the Manchester Lung Health Check programme.

Phil Crosbie

University of Manchester, Manchester

Topic: Challenges to Implementing Biomarker - Based Screening and MRD Detection

Biography

Keith Kerr graduated BSc with first class honours in Pathology in 1978, MB ChB in 1981, followed by post-graduate training in Pathology at Edinburgh University Medical School and the Royal Infirmary of Edinburgh. He obtained MRCPath in 1988, FRCPath in 1998 and was elected Honorary FRCP(Ed) in 2006. He has been a Consultant Pathologist in Aberdeen since 1989. He was awarded an Honorary Chair in Pulmonary Pathology by the University of Aberdeen in 2006.

He has been a member of IASLC for 26 years. He is a member of the IASLC Pathology Panel, Chaired this Committee 2019-2021, and now serves as Past-Chair. He was elected to the IASLC Board of Directors for four years, 2013-2017. He is an Associate Editor for the Journal of Thoracic Oncology. He has been a member of the ESMO Thoracic Educational faculty since 2013.

He was a member of the panel for the 2004, 2015 and 2021 WHO lung cancer classifications. He is a member of the International Mesothelioma Panel, and served as Pathology chair for the EORTC lung cancer group from 2006-2014. He is Pathology Chair for the ETOP Lungscape group. He has worked on numerous clinical research lung cancer trials groups (SLCF, NCRI, UKLS), guideline development for lung cancer diagnosis and management (RCPath, SIGN, NICE, BTS, ESMO, IASLC/ETOP, IASLC/CAP/AMP), conference scientific committees (ELCC, ESMO, BTOG) and other lung cancer organization committees (UKLCC, BTOG). He serves on the international Pulmonary Pathology Society council and was a British Thoracic Society member of more than 30 years. He is a regular invited speaker and faculty member at major international conferences, both in Pathology and in Thoracic Oncology.

Keith Kerr

Aberdeen University, Aberdeen

Topic: Role of the Pathologist for the Diagnosis and the Molecular Subtyping of Lung Cancer

Biography

Following studying for a BSc in Biochemistry at University of Bristol Helene completed a PhD at the University of Sheffield in 2004. In 2004 she started her career as a clinical scientist in the genetic diagnostic laboratory at St Mary’s Hospital, Manchester working across rare disease and cancer for a number of years. Helene is currently a consultant clinical scientist, leading the cancer team at the Manchester Genomic Diagnostic Laboratory and is the NW GLH solid tumour scientific lead.

Helene Schlecht

Manchester Centre for Genomic Medicine

Topic: Genomic Screening for Lung Cancer: The Role of Next Generation Sequencing

Biography

Felice Granato graduated in medicine with honours at the University of Naples, Italy, in 2005, specialising in Thoracic Surgery at the University of Siena, Italy in 2010. He has worked in United Kingdom since October 2010 and became a Fellow of Royal College of Surgeons (FRCS) of London in 2013. He graduated with a PhD in Oncology and Genetics in 2015 at University of Siena, Italy. He has worked as a consultant thoracic surgeon in the United Kingdom since April 2014 and at Manchester University NHS Foundation Trust as a consultant since February 2017. Mr Granato was appointed as Clinical Lead in Thoracic Surgery at MFT in April 2022.

Mr Granato has performed over 2000 thoracic surgical procedures and has an interest in minimally invasive surgery (70% of his practice), including advanced VATS resection and more recently robotic surgery. Additionally, his interests are in thymic surgery and mediastinal tumours, pulmonary aspergillosis, hyperhidrosis, airway interventions, pneumothorax surgery, and lung volume reduction.

Mr Granato is heavily involved in clinical research and has published more than 30 peer reviewed original articles to date. He has also co-founded the North West Thoracic Surgery Collaborative (NWTSC) and is the chair of its steering committee. The NWTSC has collected data from over 20,000 patients undergoing thoracic surgery across the UK and has produced a large number of presentations and publications since its inception, as well as supporting a UK cardiothoracic NTN to obtain a PhD. Furthermore, the NWTSC has been working closely with the Thoracic Committee of the SCTS to develop and validate a new risk prediction model, previously identified as one of the key strategic targets of the Subcommittee. A model has been successfully produced and recently externally validated, and we hope and anticipate that the model will be suitable for roll-out across the UK.

Felice Granato

Wythenshawe Hospital, Manchester

Topic: Role of Surgery for Early-Stage NSCLC

Biography

Bio coming soon

John Conibear

Barts Cancer Centre, London

Topic: Role of Radical Radiotherapy (Standard or SABR) for NSCLC

Biography

Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. Dr Newsom-Davis is Vice Chair of the British Thoracic Oncology Group Steering Committee, and leads the lung cancer service for Chelsea & Westminster Hospital.

Dr Newsom-Davis has an active clinical trials portfolio, has published his work widely, and has also presented his work at a large number of international meetings. He has been an invited lecturer for various organisations including the Royal College of Physicians, European Society of Medical Oncology, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians.

In 2015, his work on Acute Diagnostic Oncology Clinics was awarded the Macmillan Innovation Excellence Award.

Tom Newsom-Davis

Chelsea and Westminster Hospital, London

Topic: Role of Adjuvant Targeted Therapies and Immunotherapy for Completely Resected Early-Stage NSCLC

Biography

Dr McDonald has both a private and an NHS practice at The Royal Marsden. She is a Consultant Clinical Oncologist specialising in the treatment of patients with lung cancer.

Dr McDonald studied medical sciences at Cambridge University and was awarded a first-class BA (Hons) degree in 1994. She subsequently qualified from Barts and The London School of Medicine in 1997. After general medical training at St. Mary’s Hospital, she completed her specialist oncology training at The Royal Marsden and Guy's and St. Thomas’ Hospitals. She was awarded the Frank Doyle Medal from the Royal College of Radiologists in 2002.

She was awarded the president's prize for her research degree at The Institute of Cancer Research between 2008 and 2012 in individualised image-guided adaptive radiotherapy techniques for lung and bladder tumours, including implementation of lung stereotactic radiotherapy for early stage and oligometastatic lung tumours in 2009. She was subsequently appointed as a Consultant Clinical Oncologist at The Royal Marsden in 2012.

Dr McDonald's research aims to improve outcomes by developing individualised approaches to lung radiotherapy through integration of novel functional imaging and targeted biological agents with advanced radiotherapy technologies, including stereotactic/CyberKnife radiotherapy, intensity-modulated and image-guided adaptive radiotherapy. She is the clinical lead for novel developmental work on Magnetic Resonance (MR) guided adaptive radiotherapy for lung tumours.

Fiona McDonald

The Royal Marsden Hospital, London

Topic: The Role of Concurrent Chemotherapy Followed by Durvalumab

Biography

Dr Baijal is a Consultant Medical Oncologist based at The University Hospital Birmingham NHS Trust. He obtained a BSc Honours in immunology and cell pathology from University College London, before graduating with a medical degree from St. Bartholomew’s Medical School in 2001. He then returned to the Midlands to complete his general medical and oncology training and took up post as Consultant Medical Oncologist in September 2011.

Dr Baijal actively treats lung, colorectal and liver cancer patients at the Heartlands, Good Hope and Solihull sites. He specialises in all forms of cancer drug treatments including chemotherapy, immuno-oncology, precision oncology and chemo-embolisation.

Dr Baijal has a large clinical trial portfolio and is the UK Chief Investigator and Principle Investigator for national and international clinical trials. He is at the forefront of the clinical utility of liquid biopsy in managing lung and colorectal cancer patients and has several studies underway in this context. Dr Baijal has numerous publications and regularly presents at regional, national and international cancer meetings. He is on the BTOG Steering Committee and also sit on the advisory panel for the Roy Castle Lung Cancer Foundation.

Shobhit Baijal

The University Hospital Birmingham, Birmingham

Topic: The Role of Perioperative Immunotherapy for Early-Stage/Locally Advanced NSCLC

Biography

‘Prof Faivre-Finn is an Honorary Consultant Oncologist and a Professor of Thoracic Radiation Oncology at The University of Manchester with an interest in lung cancer. She trained in Paris until 1998 and took a consultant post at The Christie in 2001. She was appointed as Professor of Thoracic Radiation Oncology at the University of Manchester in 2015. Prof Faivre-Finn is an active member of several national and international research committees.’

Corinne Faivre-Finn

The Christie, Manchester

Topic: Management of Limited-Stage Small Cell Lung Cancer

Biography

‘Dr Dionysis Papadatos-Pastos is a Consultant Medical Oncologist at University College London Hospitals. He also see patients at the Princess Alexandra Hospital where he is the Clinical Lead for Acute Oncology.

He specialises in the treatment of Lung Cancer and Mesothelioma

Dr Papadatos-Pastos graduated in Medicine at the University of Athens with First Class honours. He was awarded his PhD in Medical Oncology in 2012, also with First Class honours. He completed his training in medical oncology at Guy’s and St Thomas’, St George’s University Hospitals and The Royal Marsden and undertook his specialist certificate in Medical Oncology at the Institute of Cancer Research at the University of London.

Dr Papadatos-Pastos was a recipient of the American Society of Clinical Oncology (ASCO) merit award in 2010.

Dr Papadatos-Pastos’ research interests include prognostic and predictive biomarkers, and the combination of immunotherapy drugs with novel compounds. He has participated in a number of drug trials and has presented his findings at conferences worldwide. He has been widely published in medical journals and peer-reviewed papers.’

Dionysis Papadatos-Pastos

University College London Hospitals

Topic: The Role of First-Line Immunotherapy or Chemoimmunotherapy for Advanced NSCLC

Biography

Bio coming soon

Tim Benepal

St Georges University Hospitals, NHS FT

Topic: Second-Line Therapies for Advanced NSCLC

Biography

Dr Escriu completed medical school in Barcelona and worked as a junior doctor in several UK hospitals before starting oncology training at Oxford's Churchill Hospital.

He completed a cancer biology PhD at the University of Cambridge before obtaining a higher specialist registration in Liverpool.

Dr Escriu is currently sub-specialised in thoracic oncology with a specialist interest in targeted treatments and immune therapy.

Carles Escriu

The Clatterbridge Cancer Centre, Liverpool

Topic: What's New in the Field of EGFR-Mutant Stage IV NSCLC

Biography

Dr Summers studied undergraduate medicine at the University of St Andrews and the University of Manchester, graduating in 1993 and subsequently completed higher specialist training in Medical Oncology at the Christie Hospital, Manchester between 1997 and 2004. During this period she was awarded a doctorate for research in the field of stem cell biology.

In 2004 she commenced her first post as consultant medical oncologist in the Northern Ireland Cancer Centre, Belfast, where she concentrated her efforts on establishing a medical oncology service for lung cancer patients and introducing clinical trial research.
She returned to Manchester in 2009, where she specialises in thoracic oncology, is Clinical Director for Medical Oncology at the Christie Hospital.

In addition to the clinical service, she has experience as UK chief investigator and principal investigator in commercial and academic clinical studies. She influences lung cancer research & treatment through work NHS England’s lung cancer clinical expert group (CEG) and as a clinical expert for NICE technology appraisals and was a previous member of the NIHR clinical studies group (CSG) and Chair of the LORD subgroup of the lung CSG and previously chaired the Christie Drugs and Therapeutics Committee.

Yvonne Summers

The Christie, Manchester

Topic: Standard Strategies for Advanced ALK and ROS1-Mutant NSCLC

Biography

Bio coming soon

Tanya Ahmad

University College London Hospitals

Topic: Treatment of BRAF-Mutant NSCLC

Biography

Bio coming soon

Helen Adderley

The Christie, Manchester

Topic: Treatment of KRAS-Mutant NSCLC

Biography

Dr Anna Minchom is a Consultant Medical Oncologist and BRC Clinical Scientist in the Drug Development Unit at the Royal Marsden Hospital and the Institute of Cancer Research, and the Lung Unit at the Royal Marsden Hospital.

Dr Minchom completed her undergraduate medical training in the University of Wales College of Medicine, qualifying in 2003. She was awarded MRCP in 2008. She trained in medical oncology at the Royal Marsden Hospital during which time she completed laboratory research investigating mechanisms of resistance to targeted drugs in non-small cell lung cancer, for which she was awarded an MD(res).

Dr Minchom is principal investigator on early phase drug trials including first-in-human clinical trials. Her main research focus is using a biomarker-driven and translational approach to develop novel drugs and drug combinations

Anna Minchom

Institute of Cancer Research and the Royal Marsden Hospital, London

Topic: Targeting RET and MET Positive Advanced NSCLC

Biography

Dr Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/ Christie NHS Trust. He is one of 3 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle, and has a special interest in the development of new anti-cancer drugs for patients with lung cancer. He is a member of Lung CSG, leads systemic therapy research for NSCLC in the North-East, with a portfolio of Phase I-IV studies, and is the sub-specialty lead for lung cancer for the North-East England and North Cumbria NIHR CRN. In addition he is the Principle Investigator of PROSPECT-NE a study assessing molecular profiles in patients referred for early clinical studies in Newcastle and he leads the Pharmacodynamic Biomarker team at the Northern Institute for Cancer Research, Newcastle University.

Alastair Greystoke

Newcastle University, Newcastle

Topic: Targeting EGFR exon-20, NTRK and HER2 Positive Advanced NSCLC

Biography

Bio coming soon

Nadza Tokaca

The Royal Marsden Hospital, London

Topic: First-Line Strategies for Pleural and Peritoneal Mesothelioma

Biography

Dean Fennell initially qualified with a first class degree in Pharmacology followed by Medicine and Surgery from University College London. After basic specialist training at UCL, Hammersmith, Brompton, Guy’s and St Thomas’ Hospitals in London he obtained Membership of the Royal College of Physicians, followed by a PhD in Oncology as a MRC Clinical research fellow in UCL. He completed training in Medical Oncology at St Bartholomew’s Hospital, and then undertook back-to-back Cancer Research UK Clinician Scientist Fellowships, until his current appointment in 2012. He was elected fellow of the Royal College of Physicians (London) in 2007. He served two terms on the board of the EORTC, leads a translational research laboratory and international clinical trials portfolio focused on translating novel precision medicine strategies from the lab to the clinic. He chief investigator for the CONFIRM, VIM and MiST trials in relapsed mesothelioma, a member of the IASLC & European mesothelioma taskforce, past IMIG president/NCRI mesothelioma CSG chair. He is currently director of the new Leicester Mesothelioma Research Institute focused on advancing experimental therapy for mesothelioma. Prof. Fennell has over 100 publications in journals including Nature, Nature Reviews Cancer, New England Journal of Medicine, Lancet, Lancet Oncology, Proceedings of the National Academy of Science, Nature Communications, and Journal of the National Cancer Institute.

Dean Fennell

The University of Leicester, Leicestershire

Topic: Strategies for Pre-Treated Mesothelioma: Current Standards and Future Directions

The Lung Cancer Clinical Masterclass Series

The Lung Cancer Clinical Masterclass Series is proudly co-chaired by:

Raffaele Califano

Samreen Ahmed

Available episodes

Screening and Diagnosis of Early Stage Lung Cancer

Histological Diagnosis and Genomic Subtyping for Lung Cancer

Radical Treatment for Non-Small Cell Lung Cancer (NSCLC)

Adjuvant Therapies for Completely Resected Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Radical Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Management of Small Cell Lung Cancer

Management of Stage IV Non-Small Cell Lung Cancer (NSCLC)

Management of EGFR-Mutant Stage IV Non-Small Cell Lung Cancer (NSCLC)

Management of ALK and ROS1 Gene Rearranged Non-Small Cell Lung Cancer (NSCLC)

Management of BRAF and KRAS-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Novel Molecularly Driven Targeted Therapies for Non-Small Cell Lung Cancer (NSCLC)

Management of Mesothelioma

Free registration for clinicians

Clinicians

£0

Industry

£499

Raffaele Califano

Samreen Ahmed

Haval Balata

Phil Crosbie

Keith Kerr

Helene Schlecht

Felice Granato

John Conibear

Tom Newsom-Davis

Fiona McDonald

Shobhit Baijal

Corinne Faivre-Finn

Dionysis Papadatos-Pastos

Tim Benepal

Carles Escriu

Yvonne Summers

Tanya Ahmad

Helen Adderley

Anna Minchom

Alastair Greystoke

Nadza Tokaca

Dean Fennell

The Lung
Cancer Clinical Masterclass Series

The Lung Cancer
Clinical Masterclass
Series is proudly
co-chaired by: